Shire is a biotechnology company that researches, develops, licenses, manufactures, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The Company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Shire markets its products through wholesalers, distributors, and various pharmacies.

Employee Rating

2.7More
TypePublic
HQDublin, IE
Founded1986
Size (employees)23,044 (est)
Websiteshire.com
Shire was founded in 1986 and is headquartered in Dublin, IE
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Shire

Flemming Ornskov

Flemming Ornskov

CEO
Thomas Dittrich

Thomas Dittrich

CFO
Andreas Busch

Andreas Busch

Head of Research and Development and Chief Scientific Officer
Bill Mordan

Bill Mordan

General Counsel and Company Secretary
Joanne Cordeiro

Joanne Cordeiro

Chief Human Resources Officer
Perry Sternberg

Perry Sternberg

Head of US Commercial
Show more

Shire Office Locations

Shire has offices in Dublin, Guaynabo, Cambridge, Bannockburn and in 49 other locations
Dublin, (HQ)
50 Baggot Street Lower
Sydney,
225 George St
Wien,
67 Industriestraße
Bruxelles,
47 Rue Montoyer
Chácara Santo Antonio (Zona Sul),
Av. das Nações Unidas, 14.171
Sofia,
2 2a ul. "Saborna"
Show all (54)
Report incorrect company information

Shire Financials and Metrics

Shire Revenue

Shire's revenue was reported to be £52.26 m in FY, 2017 which is a 39.3% increase from the previous period.
USD

Market capitalization (12-Dec-2018)

52.7b

Closing stock price (12-Dec-2018)

172.5
Shire's current market capitalization is $52.7 b.
Annual
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2016FY, 2017

Revenue

5.5m4.7m14.1m18.2m26.5m19.2m20.1m29.0m32.4m119.6m108.0m98.3m114.0m111.4m103.4m109.3m120.6m122.3m67.1m47.6m52.3m

Revenue growth, %

(9%)16%(2%)(7%)6%10%1%(45%)70%39%

Operating expense total

6.0m6.5m13.9m20.4m27.2m32.6m36.3m39.1m41.8m101.5m159.8m95.1m100.7m104.7m106.5m113.1m120.3m123.2m70.1m46.4m5.3b

Depreciation and amortization

1.2b1.8b
Quarterly
USDQ1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

1.5b1.7b2.4b3.7b

Cost of goods sold

227.8m778.1m1.3b1.1b

Gross profit

1.3b1.7b2.6b

Gross profit Margin, %

85%68%70%
Annual
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

45.7k219.3k17.0k4.0k135.5m528.8m

Accounts Receivable

5.0k4.0k1.2b2.6b

Prepaid Expenses

197.4m806.3m795.3m

Inventories

544.8m635.4m3.6b
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q3, 2018

Cash

74.3m64.0m69.0m728.6m369.0m209.3m

Accounts Receivable

1.1b1.3b2.6b2.8b

Prepaid Expenses

216.6m221.6m215.0m314.4m733.6m665.3m787.2m778.5m779.9m

Inventories

585.0m588.7m680.0m4.9b3.4b
Annual
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(939.6k)(1.9m)1.2m(762.0k)(179.0k)(12.2m)(9.8m)(15.1m)(10.5m)5.7m(65.5m)7.5m15.1m4.7m(1.9m)(2.7m)1.6m(2.9m)3.1m

Depreciation and Amortization

407.3m2.3b

Inventories

(63.2m)(255.8m)(145.1m)

Accounts Payable

109.2m621.6m(526.8m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

Net Income

410.4m570.0m419.0m256.9m(129.9m)375.0m

Depreciation and Amortization

120.6m1.6b

Inventories

(22.0m)(37.4m)(21.7m)(32.2m)(116.4m)(228.0m)(151.8m)(171.6m)(245.2m)

Accounts Payable

77.5m(39.8m)56.5m(154.6m)342.7m315.2m(671.5m)(445.1m)(557.8m)
Show all financial metrics

Shire Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017

Phase I Trials Products

7 6 6 7

Phase II Trials Products

11 6 10 10

Phase III Trials Products

7 14 17 15

Phase Approved

2 3 4 7
Show all operating metrics

Shire Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
BaxaltaJanuary 11, 2016$32 b
DyaxNovember 02, 2015$5.90 b
Foresight BiotherapeuticsAugust 03, 2015$300 m
Meritage PharmaFebruary 24, 2015$245 m
NPS Pharmaceuticals, Inc.January 11, 2015$5.20 b
Lumena PharmaceuticalsMay 13, 2014$260 m
Fibrotech TherapeuticsMay 02, 2014$75 m
ViroPharma IncorporatedNovember 11, 2013$4.20 b
SARcode BioscienceMarch 25, 2013$160 m
PremacureMarch 12, 2013
Show more

Shire Revenue Breakdown

Embed Graph

Shire revenue breakdown by business segment: 11.6% from Internal Medicine, 30.2% from Immunology, 18.4% from Neuroscience, 10.0% from Genetic Diseases, 26.2% from Hematology and 3.6% from Other

Human Capital Metrics

Shire's employees are reported to be approximately 52% female and 48% male.
Embed Graph
Show all human capital metrics
Report incorrect company information

Shire Online and Social Media Presence

Embed Graph
Report incorrect company information

Shire News and Updates

Takeda clears key hurdle as investors back $59 billion Shire deal

OSAKA (Reuters) - Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire, creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt.

Results of Court Meeting and Shire General Meeting

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Yield Curve, Takeda and Shire, Mueller Probe: CEO Daily for December 5, 2018

Must-read business news, delivered every morning.

Takeda’s Shareholders Agree to $58 Billion Shire Deal Despite Debt Fears

Takeda will issue $35 billion in new stock.

Takeda shareholders approve $59 billion Shire buy but are wary of debt load

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire , creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.

Takeda's Long Battle for $62 Billion Shire Deal Gets Victory

Takeda Pharmaceutical Co., has faced a string of challenges in its $62 billion pursuit of U.K.-drug maker Shire Plc.
Show more
Report incorrect company information

Shire Company Life and Culture

Report incorrect company information

Shire Frequently Asked Questions

  • When was Shire founded?

    Shire was founded in 1986.

  • Who are Shire key executives?

    Shire's key executives are Flemming Ornskov, Thomas Dittrich and Andreas Busch.

  • How many employees does Shire have?

    Shire has 23,044 employees.

  • What is Shire revenue?

    Latest Shire annual revenue is £52.3 m.

  • What is Shire revenue per employee?

    Latest Shire revenue per employee is £2.3 k.

  • Who are Shire competitors?

    Competitors of Shire include Sanofi Genzyme, Amgen and Gilead Sciences.

  • Where is Shire headquarters?

    Shire headquarters is located at 50 Baggot Street Lower, Dublin.

  • Where are Shire offices?

    Shire has offices in Dublin, Guaynabo, Cambridge, Bannockburn and in 49 other locations.

  • How many offices does Shire have?

    Shire has 54 offices.